Avecho successfully completes dosing of last patient required for Phase III interim analysis
Avecho has completed dosing of the final patient required for the interim analysis in its pivotal Phase III CBD insomnia trial, marking the final operational milestone before the upcoming interim read-out.
The interim analysis is expected to provide the first formal indication of efficacy for Avecho’s proprietary CBD TPM® formulation and represents a significant milestone for the program as it progresses toward completion.
Avecho CEO Dr Paul Gavin said:
“With 244 participants now successfully recruited and dosed, the interim analysis remains on track to be announced in late June and is expected to provide a clearer view of the product’s efficacy profile and our pathway for the future.
“With Sandoz already in place as our Australian commercial partner, a positive interim analysis would materially de-risk the program and strengthen Avecho’s position in discussions with potential partners for markets outside Australia.”